Earlier this week, Dr Fiona Godlee, editorial director of BMJ, e-mailed me in response to concerns expressed about the study of the Lightning Process published in Archives of Disease in Childhood, one of the journals under her purview. Those concerns were expressed in an open letter to her signed by 72 scientists, clinicians and other experts, along with more than 60 patient and advocacy organizations.
I sent that letter to Dr Godlee in late November. I had previously sent her the letter, with fewer signatories, in July. She had not previously responded.
Dr Godlee’s letter to me is below. It is disappointing, if not particularly surprising. In this case, BMJ’s abdication of its editorial obligations continues.
It is cold outside. My throat is scratchy, I can’t stop sneezing, and I have a runny nose. These are the typical symptoms of a human rhinovirus (HRV) infection, better known as the common cold. The average adult suffers from two to four colds a year, while the average child can experience up to ten infections per year, causing a substantial economic and public health burden.
Last last month, I resent Dr Fiona Godlee a letter criticizing BMJ’s decision to republish the Lightning Process study with the same findings. The first iteration, in July, was signed by 55 scientists, clinicians and other experts. This version was signed by more than 70 experts and over 60 patient and advocacy organizations. After I sent the previous version, more than a dozen of the signatories followed up with letters of their own to Dr Godlee.
Professor Jonathan Edwards posted this essay a while ago on the Science For ME forum. I only noticed it recently. Professor Edwards, a retired rheumatologist from University College London, has played a key role n the last few years as an advocate for patients as well as proper science. So I thought it would be helpful to share his thoughts on a topic we all wonder about: “What is ME?”
I am reposting this with Professor Edwards’ permission. The views expressed are obviously his.
From the 22nd meeting of the European Society for Clinical Virology in Copenhagen, Vincent speaks with Thea, Heli, Kim, Caroline and Irma about big data and its increasing use in virology diagnostics, epidemiology, and public health.
From the Fourth Symposium on Giant Virus Biology in Germany, Vincent, Rich, and Nels speak with Assaf, Stephen, and Alexandra about their careers and their work on giant viruses that infect ocean hosts: Emiliana huxleyi, Aureococcus anophagefferans, and a choanoflagellate.
In July, I sent Dr Fiona Godlee, editorial director of BMJ, a letter signed by 55 experts about her company’s perplexing decision to republish the originally reported–and unreliable–findings from the trial of the Lightning Process. She did not respond. This morning I sent the letter again, with more individual signatories along with dozens of patient and advocacy groups.
Dear Dr Godlee—
We are writing about the correction appended in June  to the pediatric study of the Lightning Process conducted by investigators from the University of Bristol and published by Archives of Disease in Childhood in September, 2017. The study appeared under the following title: “Clinical and cost-effectiveness of the Lightning Process in addition to specialist medical care for paediatric chronic fatigue syndrome: randomised controlled trial.” 
Adenovirus associated virus (AAV) vectors are being increasingly used for gene therapy because they are not pathogenic in humans and persist for long periods in certain cell types. Currently 120 gene delivery clinical trials with these vectors are in progress, and two have been approved: Luxturna to treat a rare form of blindness, and another for the treatment of spinal muscular atrophy. Despite these successes, improvements of the efficiency of gene delivery by these vectors are needed. In silico reconstructions of putative ancestors of AAV has led to the development of a new vector that is efficiently expressed in multiple cell types.